Merck & (MRK) Given Media Sentiment Rating of 0.16
News articles about Merck & (NYSE:MRK) have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & earned a news impact score of 0.16 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4610988059921 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- The Merck & Company, Inc. (MRK) Shares Bought by Atlas Brown Inc (iphonefresh.com)
- [$$] Lost $12 Million Windfall Sparks Suit Against Delaware (finance.yahoo.com)
- See what the IHS Markit Score report has to say about Merck & Co Inc. (finance.yahoo.com)
- $10.45 Billion in Sales Expected for Merck & Co., Inc. (MRK) This Quarter (americanbankingnews.com)
- AstraZeneca (AZN), Merck (MRK) Confirm LYNPARZA Received Additional and Broad Approval in U.S. for Ovarian Cancer (streetinsider.com)
Shares of Merck & (NYSE:MRK) traded down 0.57% during trading on Friday, reaching $61.49. The company’s stock had a trading volume of 8,421,689 shares. The company has a market cap of $167.71 billion, a PE ratio of 33.29 and a beta of 0.80. The stock’s 50 day moving average price is $62.91 and its 200 day moving average price is $63.83. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80.
Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.93 EPS. Equities research analysts predict that Merck & will post $3.87 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is 76.11%.
Several equities analysts have recently commented on MRK shares. J P Morgan Chase & Co upped their price target on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group reiterated a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Vetr upgraded shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research report on Monday, May 15th. Finally, Cowen and Company reiterated a “market perform” rating and issued a $70.00 target price (up previously from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $69.58.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.